No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
210 |
4. Check minimum number of eventsNone |
210 |
5. Include endpointsNone |
210 |
6. Filter based on genotype QC (FinnGen only) |
210 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Drug-induced tremor
based on the number of shared cases.
Similar with more cases:
- Other extrapyramidal and movement disorders in other diseases
- Extrapyramidal and movement disorders
- Neurological diseases
- Neurological diseases, wide definition
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1381 | 777 | 594 |
| Only index persons | 1216 | 696 | 520 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 65.08 | 66.43 | 63.19 |
| Only index persons | 63.63 | 65.18 | 61.55 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 210 | 116 | 94 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | 59.75 | 58.41 | 61.41 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 191
- Matched controls
- 1908
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G25.1
ICD-10 Finland
Drug-induced tremor
+∞
276.4
191
*
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
21.0
52.2
82
66
N05AH03
ATC
olanzapine; systemic
26.5
47.3
67
38
N03AG01
ATC
valproic acid; systemic, rectal
15.1
36.0
63
60
N04AA02
ATC
biperiden; systemic
38.7
35.9
45
15
R25.1
ICD-10 Finland
Tremor, unspecified
27.0
35.4
49
24
N05AH04
ATC
quetiapine; oral
8.8
35.3
90
176
C07AA05
ATC
propranolol; systemic
7.4
31.5
91
208
N05AX12
ATC
aripiprazole; systemic
19.7
26.9
41
26
G25.0
ICD-10 Finland
Essential tremor
26.6
26.9
37
17
N05AN01
ATC
lithium; oral
29.2
25.4
34
14
F31.7
ICD-10 Finland
Bipolar affective disorder, currently in remission
36.6
24.6
31
10
N05AX08
ATC
risperidone; systemic
9.2
23.9
53
76
N05AA02
ATC
levomepromazine; systemic
13.3
21.9
39
36
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
13.1
18.6
33
30
N03AX09
ATC
lamotrigine; oral
10.6
18.2
36
41
F31.30
ICD-10 Finland
Bipolar disorder Depressive episode without somatic syndrome
24.7
17.4
24
11
N05AB03
ATC
perphenazine; systemic, rectal
12.1
17.0
31
30
N05AH02
ATC
clozapine; systemic
27.4
16.4
22
9
P99
ICPC
Psychological disorders other
19.4
16.1
24
14
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
37.0
16.1
20
6
F20.9
ICD-10 Finland
Schizophrenia, unspecified
24.7
16.0
22
10
N05AF03
ATC
chlorprothixene; systemic
18.1
15.7
24
15
F29
ICD-10 Finland
Unspecified nonorganic psychosis
13.5
15.6
27
23
N05BA04
ATC
oxazepam; oral
3.9
15.0
77
283
F20.00
ICD-10 Finland
Paranoid schizophrenia continuous
27.7
15.0
20
8
N05BA01
ATC
diazepam; systemic, rectal
4.7
14.6
55
151
F31
ICD-10 Finland
Bipolar affective disorder
24.6
14.6
20
9
P72
ICPC
Schizophrenia
19.5
14.2
21
12
F31.8
ICD-10 Finland
Other bipolar affective disorders
19.5
14.2
21
12
F31.1
ICD-10 Finland
Bipolar affective disorder, current episode manic without psychotic symptoms
32.9
14.2
18
6
N06AB04
ATC
citalopram; systemic
3.9
14.1
68
235
N03AE01
ATC
clonazepam; systemic
6.8
13.9
36
63
F31.20
ICD-10 Finland
Bipolar disorder, manic episode with mood-congruent psychotic symptoms
37.1
13.8
17
5
F31.6
ICD-10 Finland
Bipolar affective disorder, current episode mixed
30.9
13.2
17
6
N05BA06
ATC
lorazepam; systemic, sublingual
7.5
13.0
31
48
F31.0
ICD-10 Finland
Bipolar affective disorder, current episode hypomanic
19.0
12.8
19
11
N05AD01
ATC
haloperidol; systemic
8.8
11.8
25
32
N05CD07
ATC
temazepam; oral
4.1
11.3
48
145
N05AF05
ATC
zuclopenthixol; systemic
46.2
11.1
13
*
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
5.4
10.8
33
71
P29
ICPC
Psychological sympt/compl other
7.2
10.4
25
39
T36
ICD-10 Finland
Poisoning by systemic antibiotics
7.6
9.6
22
32
AA1AD
NOMESCO Finland
CT of head and brain
3.0
9.4
66
289
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
4.6
8.9
31
77
F32.3
ICD-10 Finland
Severe depressive episode with psychotic symptoms
12.4
8.7
15
13
R4160
NOMESCO Finland
Other therapy enhancing rehabilitation
13.6
8.5
14
11
F31.4
ICD-10 Finland
Bipolar affective disorder, current episode severe depression without psychotic symptoms
13.6
8.5
14
11
N06AX11
ATC
mirtazapine; oral
2.6
8.5
78
397
N06AA06
ATC
trimipramine; systemic
11.5
8.5
15
14
G21.1
ICD-10 Finland
Other drug-induced secondary parkinsonism
+∞
8.4
8
*
F31.21
ICD-10 Finland
Bipolar disorder, manic episode with mood incongruent psychotic symptoms
+∞
8.4
8
*
N05AC02
ATC
thioridazine; oral
9.6
8.2
16
18
F99
ICD-10 Finland
Mental disorder, not otherwise specified
12.5
8.2
14
12
F31.3
ICD-10 Finland
Bipolar affective disorder, current episode mild or moderate depression
23.2
8.1
11
5
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
8.4
8.1
17
22
N05CF01
ATC
zopiclone; oral
2.5
7.9
79
419
F61.0
ICD-10 Finland
Mixed personality disorders
12.6
7.7
13
11
N05AA01
ATC
chlorpromazine; systemic, rectal
12.6
7.7
13
11
P73
ICPC
Affective psychosis
83.2
7.5
8
*
N06AX12
ATC
bupropion; oral
5.0
7.4
23
51
F31.2
ICD-10 Finland
Bipolar affective disorder, current episode manic with psychotic symptoms
+∞
7.3
7
*
R42
ICD-10 Finland
Dizziness and giddiness
2.8
7.3
55
244
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.6
7.3
60
284
F32.9
ICD-10 Finland
Depressive episode, unspecified
3.4
7.2
36
123
C03CA01
ATC
furosemide; systemic
2.4
7.2
73
387
N06AX16
ATC
venlafaxine; oral
3.2
7.1
39
142
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.1
7.0
27
74
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
4.1
7.0
27
74
SPAT1243
SPAT
Psychiatric/psychological examination
9.9
6.9
13
14
R53
ICD-10 Finland
Malaise and fatigue
2.6
6.8
55
255
P98
ICPC
Psychosis NOS/other
41.6
6.8
8
*
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
7.3
6.7
15
22
P74
ICPC
Anxiety disorder/anxiety state
7.9
6.5
14
19
N06AA12
ATC
doxepin; systemic
4.7
6.5
21
49
F22.0
ICD-10 Finland
Delusional disorder
11.6
6.4
11
10
F20.09
ICD-10 Finland
Paranoid schizophrenia UNS
27.7
6.3
8
*
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.9
6.2
41
167
G20
ICD-10 Finland
Parkinson disease
6.4
6.1
15
25
SPAT1240
SPAT
Therapeutic discussion
3.3
6.0
29
97
N06AB06
ATC
sertraline; oral
3.3
6.0
30
103
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
78
330
3.17
13.76
1.8
1.6
1090.0
1182.8
nmol/l
0.36
58
243
141
858
2.96
12.41
8.0
7.2
1.2
1.2
mmol/l
0.16
118
715
49
176
3.33
11.12
1.9
1.7
1.6
1.5
%
0.11
42
152
16
9
19.10
10.91
8.8
24.6
883.9
1593.4
nmol/l
—
16
9
103
570
2.58
10.33
4.3
3.0
28.9
31.6
u/l
0.36
94
540
150
1015
2.67
9.55
5.9
4.8
6.8
6.7
mmol/l
0.28
141
936
107
646
2.34
8.37
3.7
3.3
—
—
—
0
0
13
9
15.29
8.32
8.5
13.1
612.3
894.7
nmol/l
—
13
9
159
1144
2.61
8.29
7.2
4.4
5508.6
721.0
e6/l
—
5
16
90
507
2.36
8.24
3.1
2.1
408.9
193.4
u/l
1.00
81
473
123
799
2.30
7.96
6.9
6.1
1.2
1.2
mmol/l
0.37
111
726
110
684
2.28
7.89
2.4
2.0
83.4
94.7
pmol/l
1.83
58
343
32
109
3.28
7.79
2.3
1.4
—
—
—
0
0
71
368
2.40
7.78
1.7
1.7
106452099.0
456.8
pmol/l
0.49
62
298
143
1005
2.33
7.47
15.7
9.4
4.1
4.2
e9/l
0.12
126
881
31
107
3.23
7.38
2.6
1.5
—
—
—
0
0
115
751
2.17
7.05
4.9
4.6
35.0
35.4
g/l
0.31
110
703
41
172
2.72
6.91
4.4
4.6
1.6
2.0
mmol/l
0.35
35
136
173
1345
2.62
6.84
8.2
7.4
77.0
79.4
u/l
0.32
167
1246
73
418
2.14
6.08
2.2
2.0
3.2
3.1
mg/l
0.06
59
359
58
309
2.21
5.75
3.0
2.9
2.0
0.9
e6/l
1.09
40
180
66
371
2.14
5.72
6.9
4.2
1.0
1.0
kg/l
0.17
11
51
55
289
2.22
5.63
2.9
3.6
0.8
0.8
mmol/l
0.22
49
270
103
689
1.97
5.48
2.7
2.3
72.9
76.1
nmol/l
0.55
87
601
46
228
2.30
5.39
6.3
6.0
1.1
1.1
mmol/l
0.91
39
209
86
544
1.98
5.35
3.4
2.3
57.8
56.4
u/l
0.19
81
502
41
199
2.32
5.03
2.2
1.9
—
—
—
0
0
82
521
1.94
4.96
3.1
3.1
0.3
0.4
e6/l
0.26
70
394
42
209
2.26
4.86
5.0
7.0
1.4
1.3
mmol/l
0.02
30
173
52
285
2.10
4.72
2.7
2.0
—
—
—
0
0
40
202
2.21
4.45
2.2
2.0
—
—
—
0
0
87
582
1.84
4.38
2.5
3.3
2.4
2.3
mmol/l
0.53
77
506
7
6
12.01
4.30
2.9
1.0
—
—
—
0
0
98
689
1.79
4.13
5.7
4.0
36.6
38.2
ng/l
0.06
76
495
156
1266
1.90
4.02
6.0
3.8
14.4
14.9
pmol/l
1.55
146
1124
24
101
2.55
3.99
2.5
1.9
—
—
—
0
0
50
287
1.97
3.96
3.4
3.2
3.6
2.2
e6/l
0.47
32
160
142
1122
1.82
3.96
5.2
3.1
52.4
48.3
u/l
0.25
132
1044
11
30
3.81
3.69
1.8
1.3
—
—
—
0
0
11
30
3.81
3.69
1.8
1.3
—
—
—
0
0
66
424
1.81
3.68
1.6
1.6
20.5
21.4
nmol/l
0.18
56
358
14
46
3.19
3.60
1.4
1.2
—
—
—
0
0
6
6
10.24
3.52
1.0
1.2
—
—
—
0
0
6
6
10.24
3.52
1.0
1.2
—
—
—
0
0
181
1570
2.11
3.50
7.1
4.5
2.0
1.9
mu/l
0.43
163
1414
113
855
1.70
3.49
6.0
3.9
0.0
0.0
estimate
0.00
14
174
56
350
1.82
3.39
4.2
3.7
279.7
415.6
ng/l
0.21
42
276
6
7
8.78
3.28
1.0
1.4
—
—
—
0
0
113
871
1.64
3.13
6.3
3.9
0.0
0.0
estimate
0.00
14
168
112
862
1.64
3.11
8.8
5.3
0.0
0.0
estimate
0.00
13
175
21
94
2.37
3.08
1.7
3.0
4.2
4.3
pmol/l
0.17
15
81
25
122
2.19
3.02
7.5
4.1
5.2
5.1
kpa
0.37
25
116
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
14
52
2.81
2.95
2.4
2.6
0.2
0.4
u/ml
—
8
25
6
10
6.14
2.71
2.0
1.2
—
—
—
0
0
5
7
7.28
2.56
1.0
1.3
—
—
—
0
0
5
7
7.28
2.56
1.0
1.3
—
—
—
0
0
6
11
5.58
2.56
2.0
1.3
—
—
—
0
0
34
198
1.86
2.55
7.6
7.7
—
—
—
0
0
152
1296
1.63
2.53
4.5
4.1
12.7
12.1
mm/h
0.18
142
1179
67
476
1.60
2.46
5.9
4.2
0.0
0.0
estimate
0.00
13
170
74
541
1.57
2.40
3.2
3.4
2982.0
1288.2
ng/l
0.72
66
455
188
1710
1.95
2.33
24.4
14.6
20.5
23.0
mg/l
0.65
161
1350
89
684
1.52
2.29
6.9
4.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
9
5.66
2.22
1.2
1.2
—
—
—
0
0
5
9
5.66
2.22
3.0
1.8
62.4
51.3
umol/l
—
5
9
26
147
1.88
2.14
1.7
2.4
6.2
8.4
ug/l
0.30
18
135
93
732
1.49
2.09
3.0
2.6
130.6
118.9
ug/l
0.21
83
665
54
381
1.56
2.01
1.9
1.9
0.9
1.3
mg/l
1.07
42
311
11
45
2.52
1.96
2.5
1.6
—
—
—
0
0
53
377
1.54
1.90
1.5
1.2
3.3
1.5
u/ml
—
7
89
7
22
3.25
1.89
1.0
1.2
—
—
—
0
0
7
23
3.11
1.81
1.0
1.2
—
—
—
0
0
172
1555
1.59
1.80
30.5
15.1
35.5
39.7
%
3.33
111
1102
5
13
3.91
1.72
1.0
1.2
1.6
1.8
mmol/l
—
5
13
179
1647
1.59
1.58
6.2
4.6
6.1
6.0
mmol/l
1.01
161
1495
17
95
1.86
1.48
4.5
3.3
1.2
1.3
%
0.23
17
95
26
166
1.65
1.46
5.3
6.8
1.1
1.2
mmol/l
0.17
26
156
24
150
1.68
1.45
1.6
2.1
—
—
—
0
0
193
1817
1.77
1.45
27.8
17.1
83.8
77.6
umol/l
1.37
193
1817
22
136
1.69
1.39
2.5
2.8
58.2
63.0
ml/min/173m2
—
7
62
12
62
1.99
1.30
3.6
1.9
—
—
—
0
0
8
35
2.34
1.28
1.6
1.6
—
—
—
0
0
115
1003
1.32
1.20
3.0
3.1
—
—
—
0
0
5
20
2.54
1.16
2.0
1.7
—
—
—
0
0
5
21
2.41
1.09
2.0
1.7
—
—
—
0
0
5
21
2.41
1.09
2.0
1.7
—
—
—
0
0
5
21
2.41
1.09
2.0
1.7
—
—
—
0
0
5
21
2.41
1.09
1.4
1.8
—
—
—
0
0
24
163
1.53
1.07
2.0
2.3
—
—
—
0
0
42
321
1.39
1.04
2.2
2.8
2.4
2.4
mmol/l
0.05
33
272
5
22
2.30
1.04
2.0
1.6
—
—
—
0
0
5
22
2.30
1.04
2.0
1.6
—
—
—
0
0
50
400
1.33
0.93
3.6
2.4
—
—
—
0
0
10
56
1.83
0.89
1.7
1.4
—
—
—
0
0
170
1597
1.34
0.88
19.7
13.6
75.0
80.0
ml/min/173m2
1.61
145
1303
6
30
2.03
0.87
1.0
1.4
—
—
—
0
0
10
57
1.79
0.85
2.9
2.8
—
—
—
0
0
11
65
1.73
0.84
4.0
2.2
—
—
—
0
0
91
804
1.23
0.76
5.5
4.2
—
—
—
0
0
26
194
1.39
0.76
5.0
4.6
31.5
33.0
%
0.27
15
123
13
194
0.65
0.75
4.3
3.5
—
—
—
0
0
7
40
1.78
0.72
3.0
4.8
32.3
25.3
mg/l
—
7
25
166
1572
1.27
0.68
7.6
5.9
41.2
40.0
mmol/mol
0.82
154
1463
5
29
1.74
0.64
1.0
1.3
—
—
—
0
0
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
23
293
0.76
0.57
2.5
1.5
—
—
—
0
0
173
1657
1.25
0.56
5.0
4.5
1.3
1.5
mmol/l
4.48
156
1510
8
125
0.63
0.56
1.5
1.7
—
—
—
0
0
6
37
1.64
0.56
1.2
1.4
—
—
—
0
0
24
299
0.78
0.51
1.3
1.3
8.5
30.0
iu/ml
—
6
93
54
471
1.20
0.50
2.4
2.8
8458.6
7043.9
umol/l
0.06
48
397
7
45
1.57
0.49
1.0
1.1
—
4.8
—
0
5
7
46
1.54
0.49
1.1
1.9
—
—
—
0
0
177
1708
1.23
0.47
5.5
5.1
2.5
2.7
mmol/l
2.15
160
1557
173
1666
1.22
0.47
5.0
4.5
4.4
4.6
mmol/l
2.19
159
1531
7
50
1.41
0.45
1.3
1.7
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
3.1
—
116.1
—
0
16
29
343
0.82
0.40
2.4
3.1
0.8
0.8
ug/l
0.05
17
236
12
89
1.37
0.39
1.8
1.9
—
—
—
0
0
5
37
1.36
0.37
1.4
1.7
—
—
—
0
0
6
44
1.37
0.34
1.5
1.4
—
—
—
0
0
30
257
1.20
0.34
1.9
1.4
—
—
—
0
0
7
52
1.36
0.31
1.3
1.7
—
—
—
0
0
7
57
1.24
0.29
3.1
2.3
25.2
24.9
mmol/l
—
7
49
5
39
1.29
0.23
1.0
1.3
—
—
—
0
0
22
192
1.16
0.21
1.5
4.2
3.1
29.4
ug/l
0.59
15
150
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
10
80
1.26
0.21
1.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
2.1
—
—
—
0
0
12
99
1.22
0.20
6.3
9.0
24.5
24.8
mmol/l
0.12
12
89
6
50
1.21
0.20
1.3
2.1
—
—
—
0
0
6
53
1.14
0.19
1.7
1.2
—
—
—
0
0
164
1608
1.09
0.17
4.6
4.0
1.6
1.3
mmol/l
3.13
150
1462
8
72
1.12
0.16
1.1
2.3
—
—
—
0
0
50
471
1.08
0.15
4.3
4.4
25.7
21.2
%
1.27
23
227
62
590
1.07
0.14
4.2
5.0
2.0
2.5
ug/l
0.34
53
526
5
46
1.09
0.09
1.2
1.2
—
—
—
0
0
5
47
1.07
0.09
1.0
1.4
—
—
—
0
0
27
253
1.08
0.09
3.5
2.4
23.9
23.1
%
0.08
21
218
6
54
1.11
0.09
1.5
1.1
—
—
—
0
0
7
66
1.06
0.08
1.1
2.4
12.0
10.1
g/l
—
7
59
9
84
1.07
0.07
1.6
1.3
—
—
—
0
0
47
461
1.03
0.02
1.5
1.7
1.4
1.3
mmol/l
0.07
39
381
27
278
0.97
0.02
1.3
1.3
1.1
8.3
u/ml
—
8
116
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
10.9
—
0
5
0
7
0.00
0.00
0.0
8.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.6
—
16.5
—
0
8
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
6
61
0.98
0.00
1.0
2.7
0.2
0.7
g/l
—
6
55
5
58
0.86
0.00
1.2
1.8
—
—
—
0
0
7
77
0.91
0.00
1.0
2.7
46.3
41.6
u/l
—
7
71
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
5
58
0.86
0.00
1.0
2.5
35.6
37.4
g/l
—
5
51
5
54
0.92
0.00
1.6
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
6
69
0.87
0.00
1.0
1.9
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
7
0.00
0.00
0.0
2.6
—
119.1
—
0
7
Mortality – FinRegistry
↥Association
Association between endpoint DRUGADVERS_TREMOR and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| DRUGADVERS_TREMOR | 1.727 [1.43, 2.08] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.175 |
During the follow-up period (1.1.1998 — 31.12.2019), 219 out of 683 females with DRUGADVERS_TREMOR died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| DRUGADVERS_TREMOR | 2.187 [1.73, 2.77] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 212 out of 529 males with DRUGADVERS_TREMOR died.
Mortality risk
Mortality risk for people of age
years, who have DRUGADVERS_TREMOR.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.176% | 0.271% |
| 5 | 1.097% | 2.284% |
| 10 | 2.546% | 5.616% |
| 15 | 4.83% | 10.66% |
| 20 | 8.486% | 17.829% |
Relationships between endpoints
↥Index endpoint: DRUGADVERS_TREMOR – Drug-induced tremor
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data